These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18444830)

  • 1. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study.
    Rodriguez-Barradas MC; Goulet J; Brown S; Goetz MB; Rimland D; Simberkoff MS; Crothers K; Justice AC
    Clin Infect Dis; 2008 Apr; 46(7):1093-100. PubMed ID: 18444830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.
    Teshale EH; Hanson D; Flannery B; Phares C; Wolfe M; Schuchat A; Sullivan P
    Vaccine; 2008 Oct; 26(46):5830-4. PubMed ID: 18786586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ≥60 years-a population-based retrospective cohort study.
    Kolditz M; Schmitt J; Pletz MW; Tesch F
    Clin Microbiol Infect; 2018 May; 24(5):500-504. PubMed ID: 28830805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
    Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
    Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting.
    Johnstone SL; Moore DP; Klugman KP; Madhi SA; Groome MJ
    Paediatr Int Child Health; 2020 Feb; 40(1):50-57. PubMed ID: 31156062
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.
    Peñaranda M; Falco V; Payeras A; Jordano Q; Curran A; Pareja A; Samperiz G; Dalmau D; Ribera E; Riera M
    Clin Infect Dis; 2007 Oct; 45(7):e82-7. PubMed ID: 17806042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
    Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
    BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
    Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults.
    French N; Gordon SB; Mwalukomo T; White SA; Mwafulirwa G; Longwe H; Mwaiponya M; Zijlstra EE; Molyneux ME; Gilks CF
    N Engl J Med; 2010 Mar; 362(9):812-22. PubMed ID: 20200385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.
    Rossheim AE; Young AM; Siik J; Cunningham TD; Troy SB
    Hum Vaccin Immunother; 2016 Aug; 12(8):2117-2123. PubMed ID: 27172241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Zou X; He J; Zheng J; Liang M; Gao J; Huang J; Jiang Y; Jiang Y; Chen X
    Vaccine; 2022 Jan; 40(1):37-42. PubMed ID: 34857419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting.
    Garcia Garrido HM; Mak AMR; Wit FWNM; Wong GWM; Knol MJ; Vollaard A; Tanck MWT; Van Der Ende A; Grobusch MP; Goorhuis A
    Clin Infect Dis; 2020 Jun; 71(1):41-50. PubMed ID: 31634398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children: a retrospective, population-based, record-linked cohort study.
    Fathima P; Gidding HF; McIntyre PB; Snelling TL; McCallum L; de Klerk N; Blyth CC; Liu B; Moore HC
    Lancet Child Adolesc Health; 2019 Oct; 3(10):713-724. PubMed ID: 31439496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.
    Vila-Corcoles A; Hospital-Guardiola I; Ochoa-Gondar O; de Diego C; Salsench E; Raga X; Fuentes-Bellido CM
    BMC Public Health; 2010 Jan; 10():25. PubMed ID: 20085658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study.
    Hechter RC; Chao C; Jacobsen SJ; Slezak JM; Quinn VP; Van Den Eeden SK; Tseng HF
    Vaccine; 2012 Aug; 30(38):5625-30. PubMed ID: 22789510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.
    Madhi SA; Kuwanda L; Cutland C; Klugman KP
    Clin Infect Dis; 2005 May; 40(10):1511-8. PubMed ID: 15844075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.